Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Net Cash Flow (2016 - 2026)

Anika Therapeutics has reported Net Cash Flow over the past 17 years, most recently at -$16.4 million for Q1 2026.

Quarterly Net Cash Flow fell 321.77% to -$16.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$12.3 million through Mar 2026, up 19.86% year-over-year, with the annual reading at $236000.0 for FY2025, 101.51% up from the prior year.
Net Cash Flow was -$16.4 million for Q1 2026 at Anika Therapeutics, down from -$444000.0 in the prior quarter.
Over five years, Net Cash Flow peaked at $5.6 million in Q3 2023 and troughed at -$16.4 million in Q1 2026.
The 5-year median for Net Cash Flow is -$3.6 million (2022), against an average of -$3.1 million.
Year-over-year, Net Cash Flow crashed 1433.3% in 2023 and then surged 747.91% in 2025.
A 5-year view of Net Cash Flow shows it stood at -$1.4 million in 2022, then skyrocketed by 254.96% to $2.1 million in 2023, then tumbled by 337.34% to -$5.1 million in 2024, then skyrocketed by 91.26% to -$444000.0 in 2025, then crashed by 3600.9% to -$16.4 million in 2026.
Per Business Quant, the three most recent readings for ANIK's Net Cash Flow are -$16.4 million (Q1 2026), -$444000.0 (Q4 2025), and $5.1 million (Q3 2025).